BeOne Medicines: Beat-and-Raise Quarter Anchored by BRUKINSA Durability and a Pipeline Inflection
Q2 revenue grows 30% to $1.7B, MANGROVE sets up BRUKINSA for frontline MCL, and BEQALZI adds a new mechanism — management lifts full-year guidance.
BGNE · Earnings Call · 2026-08-05
Commercial Engine at Full Throttle
BeOne Medicines delivered a strong beat-and-raise quarter, with total revenue of $1.7 billion, up 30% year-over-year, and GAAP EPS of $2.05, up 144% year-over-year. The core driver remains BRUKINSA, which generated over $1.2 billion in global sales, growing 31%. John Oyler highlighted the durability of the franchise: "More than 6.5 years after its initial launch, BRUKINSA is seeing its highest level of sustained new patient starts showing favorable early trends in duration of therapy, and it's showing strong growth across all five approved indications." This performance is not just a one-off; it is supported by real-world evidence and a broadening label. The company's earnings growth is accelerating, and the market has taken notice. U.S. sales reached $893 million, up 31%, with new patient starts at an all-time high. Aaron Rosenberg noted, "Total revenue for the quarter was $1.7 billion, representing 30% growth compared to the prior year." The Amgen in-licensed portfolio grew 25%, and TEVIMBRA maintained leadership in China. The approval process is also advancing, with BEQALZI gaining FDA approval in mantle cell lymphoma and the MANGROVE study showing BRUKINSA plus rituximab as a potential frontline standard.
Stepping back, BeOne is the only company in the world with foundational medicines across the three mechanisms of action for B-cell malignancies.
Pipeline Inflection: MANGROVE and BEQALZI
The quarter marked a major pipeline inflection. The Phase III MANGROVE study met its primary endpoint, demonstrating that BRUKINSA plus rituximab is superior to chemotherapy in frontline mantle cell lymphoma. Lai Wang said, "BRUKINSA plus rituximab has the potential to redefine frontline treatment and become the first chemo-free regimen for these patients." This is a groundbreaking result, as no prior BTK inhibitor combination has shown superiority over chemo. The company is preparing global submissions in 2H 2026. BEQALZI, the first BCL-2 inhibitor approved for MCL, adds a new mechanism to the portfolio, and the company already has probability of success for further indications. The pipeline also includes a CDK4 inhibitor, B7-H4 ADC, and GPC3×4-1BB bispecific, all advancing to registrational trials. The Phase 1 study for PRMT5 inhibitor has shown proof of concept in NSCLC, with ESMO data expected soon. This breadth of innovation is rare and positions BeOne for sustainable growth.
Financial Discipline and Raised Guidance
Adjusted operating income grew 80% to $503 million, and adjusted EPS rose to $3.84 from $2.25 a year ago. Free cash flow doubled to $435 million, demonstrating the scalability of the model. Management raised 2026 revenue guidance by $300 million to $6.6–$6.8 billion and non-GAAP operating income to $1.7–$1.8 billion. The raise reflects confidence in BRUKINSA's momentum and the pipeline's potential. As Aaron said, "We continue to demonstrate the scalability of our model in the quarter with income from operations growing to $325 million." While operating expenses will rise in 2H to fund pipeline development, the company remains committed to growth with measured margin expansion.
Outlook
With six Phase III readouts expected over the next three years and a growing portfolio, BeOne is entering a phase of multiple value inflection points. The company's ability to combine commercial strength with deep science sets it apart. As John Oyler concluded, "It's an incredibly exciting time for our company, for our portfolio and for our pipeline." The market has a strong story to follow, and the next catalysts—ESMO data, MANGROVE full data, and potential approvals—are ahead.